Phase
Startup
Diagonal Bio
Diagonal Bio AB is a MedTech company based in Lund (Sweden), founded in 2020. Our goal is to fundamentally change the infectious disease testing landscape as we know it today.
Founded during the Covid-19 crises towards a transition to become a professional company with major growth ambitions on the path to listing on Nasdaq First North Growth Market.
Major steps from the initial startup founded during the Covid-19 Crises towards a transition to become a professional company with major growth ambitions on the path to listing on Nasdaq First North Growth Market. We have come a long way in a very short time and continue to optimize and focus our effort to get the first product to market and we are confident in the opportunities to continue to develop as a commercial company driven by a strong and experienced team that will enable us to continue at the same high pace during the rest of the year.
This is truly an exciting journey with the potential to limit the spread of disease worldwide, hence our efforts will have a direct impact on the lives and health of individuals at a global scale.
Non-invasive cardiac pressure monitoring device
Accelerated drug development in oncology
Unique stem cell therapeutics
3D cell culture systems
Rapid Diagnostics for Multi-pathogen detection
Individualised information of the intestinal flora
Imaging solutions for life sciences
Novel probiotics for therapeutic effect
Treatments based on nature’s own defenses
Pest control solutions for bed bugs
Neonatal Lung Analyzer
Prebiotics for irritable bowel syndrome
Nanotechnology based infection control
Excellence in designing & executing drug discovery
Models for autoimmune & inflammatory conditions
Ultrasensitive cancer diagnostics & monitoring
Structural biology & drug discovery services
Male-Factor Infertility Diagnostics
Customized in vitro and in vivo services
Stroke detection device
Wound treatment gel
Regenerative medicine & cancer
